Haleon completes share buyback with Pfizer exit

Published 19/03/2025, 08:06
Haleon completes share buyback with Pfizer exit

LONDON - Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has announced the purchase of 44,155,844 of its ordinary shares from Pfizer Inc. (NYSE:PFE) at a price of £3.85 per share, totaling approximately £170 million. This transaction, which took place off-market, is part of Haleon’s £500 million share buyback program for 2025 and follows the company’s previous announcement on February 27, 2025.

The shares acquired from Pfizer will be cancelled, reducing Pfizer’s interest in Haleon from approximately 7.3% to nil. This marks a significant shift in Haleon’s shareholder structure, as Pfizer had held a 32% stake at the time of Haleon’s demerger in July 2022.

Brian McNamara, CEO of Haleon, stated that this move aligns with the company’s disciplined capital allocation priorities and supports their commitment to delivering attractive returns for shareholders. He emphasized Haleon’s strong financial position and readiness to capitalize on future opportunities.

The completion of this share purchase from Pfizer, alongside Pfizer’s own offering to institutional investors, signifies Pfizer’s full exit from its investment in Haleon. The company will make an additional announcement once the off-market purchase is finalized.

Haleon’s portfolio includes well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, spanning across major health categories like Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS).

This information is based on a press release statement from Haleon plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.